Antimalarial therapy during pregnancy poses important safety concerns due to potential teratogenicity and maternal physiological and biochemical changes during gestation. Piperaquine (PQ) has gained interest for use in pregnancy in response to increasing resistance towards sulfadoxine-pyrimethamine in sub-Saharan Africa. Coinfection with HIV is common in many developing countries, however, little is known about the impact of antiretroviral (ARV) mediated drug-drug interaction (DDI) on piperaquine pharmacokinetics during pregnancy. This study applied mechanistic pharmacokinetic modelling to predict pharmacokinetics in non-pregnant and pregnant patients, which was validated in distinct customised population groups from Thailand, Sudan and Papua New Guinea. In each population group, no significant differences in day 7 concentrations were observed during different gestational weeks (GW) (weeks 10-40), supporting the notion that piperaquine is safe throughout pregnancy with consistent pharmacokinetics, although possible teratogenicity may limit this. Antiretroviral-mediated DDIs (efavirenz and ritonavir) had moderate effects on piperaquine during different gestational weeks with a predicted AUC ratio in the range 0.56-0.8 and 1.64-1.79 for efavirenz and ritonavir, respectively, over GW 10-40, with a reduction in circulating human serum albumin significantly reducing the number of subjects attaining the day 7 (post-dose) therapeutic efficacy concentrations under both efavirenz and ritonavir DDIs. This present model successfully mechanistically predicted the pharmacokinetics of piperaquine in pregnancy to be unchanged with respect to non-pregnant women, in the light of factors such as malaria/HIV co-infection. However, antiretroviral-mediated DDIs could significantly alter piperaquine pharmacokinetics. Further model refinement will include collation of relevant physiological and biochemical alterations common to HIV/malaria patients.
| INTRODUCTION
The problem of malaria-induced maternal morbidity and mortality in endemic areas for the disease is far reaching, particularly with respect to the unborn child. Maternal death due to malaria was reported to account for up to 25% of maternal deaths due to all causes in malaria endemic regions, while close to a million children born to malaria-infected mothers had low birth weights (Consortium, 2017 ).
Malarial infection in pregnancy triples the maternal risk of suffering from severe diseases compared with non-pregnant women (Murray & Bennett, 2009) . This is further confounded by the added complication of coinfection with human immunodeficiency virus (HIV) as a result of the immunocompromised nature of pregnancy (Menendez et al., 2008; Ofori et al., 2009; Schantz-Dunn & Nour, 2009 ).
The treatment of malaria during pregnancy poses major challenges to healthcare systems. This is because antimalarial treatments (AMT) that yield satisfactory safety and efficacy profiles are often found to be unsafe during the early stages of pregnancy (Nosten et al., 2006) . The WHO 0 s current recommendations for antimalarial treatment chemoprophylaxis are based on intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) (WHO, 2015) . This recommendation was based on a review (Kayentao et al., 2013) of seven trials that assessed the use of monthly sulfadoxine-pyrimethamine administration for malaria prevention in pregnant women across six African countries. The result of the review demonstrated that there was a significant reduction in both low birth weights and placental and maternal parasitaemia following administration of no less than two doses of sulfadoxine-pyrimethamine monthly during pregnancy (Kayentao et al., 2013) .
However, with the spread of SP resistance, new interventions have been sought. In high transmission settings where there may be widespread resistance to SP-IPTp, dihydroarteminisin-piperaquine (DHA-PQ) has been demonstrated to result in a lower malarial burden (Kakuru et al., 2016) . A recent study showed that, when compared with the use of SP in pregnant women, the administration of DHA-PQ provided significantly higher protection against placental malaria; significantly lowered maternal parasitaemia and reduced the prevalence of composite adverse birth consequences (Kakuru et al., 2016) . More so, the safety of DHA-PQ in pregnancy is evident in numerous studies.
In 2015, a randomised controlled superiority trial showed that in addition to the observed efficacy of DHA-PQ for preventing malaria in pregnancy, DHA-PQ resulted in fewer detrimental maternal and infant side effects compared with SP-IPTp (Desai et al., 2015) . Similarly, another study revealed that compared with quinine, DHA-PQ used for the treatment of multi-resistant malaria in the 2nd and 3rd trimester of pregnancy resulted in less perinatal mortality, although in the 1st trimester quinine appeared to be safer (Poespoprodjo et al., 2014) .
Infectious diseases such as HIV are prevalent in malaria endemic regions (Benjamin et al., 2015; Tarning et al., 2012) . Pregnant women with HIV and malaria coinfection are more vulnerable to all the complications of malaria in pregnancy such as anaemia, placental parasitaemia and low birth weights (Hayes et al., 2015) . This can be further confounded by the potential for many antiretroviral (ART) drugs to elicit drug-drug interactions (DDIs) on common Cytochrome P450 isozymes, e.g. 3A4 (Fichtenbaum & Gerber, 2002; Horita & Doi, 2014; Renjifo et al., 2015) . Hence, these factors are significant causes for concern when treating this population. The reduced systemic concentration of DHA-PQ, due to coadministration with efavirenz in HIV infected pregnant women, has been demonstrated in a recent study which showed that in Ugandan pregnant women, the AUC 0-8hr and AUC 0-21d of piperaquine was 50% and 40% lower, respectively, when DHA-PQ was co-administered with efavirenz compared with when DHA-PQ was taken alone (Kajubi et al., 2017a) . A systemic review of data involving DDI between antiretroviral drugs and antimalarial treatments further accentuated the likelihood of a range of such DDIs (Seden et al., 2017) .
Addressing the problem of antimalarial treatments in malaria endemic areas requires consideration of physiological peculiarities in subjects that might impact upon the efficacy of the antimalarial treatment. Some examples of the factors that can impact upon the efficacy of antimalarial treatment include, but are not limited to, geographical region differences in body weight (Hayes et al., 2015) and biochemistry, for example, serum albumin (Nanjul, 2007) and haematocrit (Newton et al., 2013; Othman, 2014 were incorporated into the design of the population groups.
| METHODS
All population based PBPK modelling was conducted using the virtual clinical trials simulator Simcyp (Simcyp Ltd, a Certara company, Sheffield, UK, Version 16).
| Model development
A four-stage stepwise approach was employed for model development ( Figure 1 ) which is fully described in the supplementary materials and briefly summarised below.
| Base model development (Step 1)
The base model was developed from two reported studies of piperaquine dosed in fasted Caucasian healthy volunteers (Ahmed et al., 2008; Sim, Davis, & Ilett, 2005) . Given the high lipophilicity and expected widespread tissue distribution of piperaquine, a full PBPK model was employed for all model simulations.
| Non-pregnant malaria population groups (Step 2)
To assess the predictive performance of the model in non-Caucasian non-complicated malaria population groups, we identified four studies in which piperaquine was dosed to non-pregnant females in Thailand (Rijken et al., 2011; Tarning et al., 2012) (Tarning et al., 2008 was excluded from thus study due to the difficulty in obtaining individual data points for the study duration), Papua New Guinea (Benjamin et al., 2015) and Sudan (Hoglund et al., 2012) . The 'Healthy Volunteer'
(HV) population group within Simcyp was adapted, in order to address the differences in patient demographics (primarily body weight) and biochemistry (haematocrit/plasma proteins) between healthy-subjects and malaria-subjects (see supplementary materials Table S1 ).
| Pregnant malaria population groups (Step 3)
The 'Pregnancy' population group within Simcyp was adapted (see supplementary materials) to create 'Malaria-Pregnancy' population groups based upon the three regional populations originating from the four clinical studies highlighted in section 2.1.2. These studies also detailed the pharmacokinetics of piperaquine in pregnant women and this was used as a basis to further validate the 'Malaria-Pregnancy' population groups. Final model parameters for piperaquine are detailed in supplementary materials Table S2 .
| 'what-if' scenarios (Step 4)
To assess 'What-If' scenarios (Figure 1 ), case studies were included, in order to demonstrate the impact of possible drug-drug interactions mediated by efavirenz (EFV) or ritonavir (RTV); the former was selected due to the potential for CYP3A4 induction and the latter for its CYP3A4 inhibitory effects.
Efavirenz/ritonavir-mediated drug-drug interactions
The validation of DDIs mediated by antiretroviral treatment was considered through the only published DDI study available (Kajubi et al., 2017b ) with efavirenz and piperaquine in a Ugandan population group.
A Ugandan population group was developed (see supplementary materials for details) and the trial design was replicated for the three arms of the study within the reported trial, namely non-pregnant women with no-DDI, pregnant women with no-DDI and pregnant women with a DDI scenarios, in order to compare the ability of the PQ PBKP model to capture the extent of the reported DDIs.
Subsequently, DDIs were simulated in a 10 × 10 virtual clinical trial with each population group described previously (see section 2.1.2). A standard daily dose approach was employed for efavirenz (600 mg once daily) and ritonavir (100 mg twice daily, in line with ritonavir/lopinavir combination dosing of 100 mg/400 mg twice daily) with EFV/RTV dosed for 14 days and piperaquine dosed on days 3, 4 and 5 (10 mg/kg piperaquine base). The malaria-pregnancy population groups were redefined during the simulation duration on a daily basis to account for physiological/biochemical changes, and studies conducted across gesta- 
Human serum albumin
Human serum albumin (HSA) concentrations were set at 20 g/l and 50 g/l within population groups, to mimic the reduction in serum albumin reported at different stages of malaria infection, with 20 g/l representing severe malaria (Sagaki et al., 2013) . The Simcyp 'Pregnancy' population includes a description for alterations in HSA during pregnancy and the baseline initial HSA concentration was fixed at the aforementioned concentrations.
Gestational week
The impact of gestation week on piperaquine pharmacokinetic during EFV/RTV-mediated DDI was further assessed at weeks 10, 20 and 30 for all population groups.
| Predictive performance
Although no uniform criterion has been accepted for defining an 'optimal' predictive performance range, a prediction to within 2-fold of the observed data is generally accepted in this context (Sager, Yu, Ragueneau-Majlessi, & Isoherranen, 2015) and was employed as our criterion for C max and AUC comparisons with those clinically reported.
For the EFV/RTV DDI simulation, as the clinical efficacy of piperaquine is determined by its day 7 concentration (post-first dose) of 30 ng/ml (Price et al., 2007) , the impact of a DDI on piperaquine pharmacokinetics was assessed by direct analysis of the day 7 concentration.
| Data analysis
Unless otherwise stated, all simulations of plasma concentrationtime profiles were presented as the arithmetic mean and the 5-95th percentiles. Reported concentration-time profiles from clinical studies were digitally retrieved using the WebPlotDigitizer v3.10 393 ng h/ml ± 149 ng h/ml; AUC 0-last : 2312 ng h/ml ± 790 ng h/ml) ( Figure 2a ) and Sim et al. (2005) [1566-5070 μg h/l]) for a 500 mg PQP dose (Figure 2c ). For a higher 1500 mg PQP dose, consistent simulated C max (76.1 ng/ml ± 69 ng/ml), t max (5.1 h) and AUC (AUC 0-24 :
1243 ng h/ml ± 193.8 ng h/ml; AUC 0-last : 9065 ng h/ml ± 1299 ng h/ml) were simulated when compared with Ahmed et al. (2008) (C max : 147 ng/ml ± 110 μg/l; t max : 2.5 h; AUC 0-24 : 1418 ng h/ml ± 775 ng h/ml; AUC 0-t : 6399 ng h/ml ± 2067 ng h/ml) ( Figure 2b ).
These predictions supported the successful model development in healthy-volunteer population groups for fasted single dose studies only.
3.2 | Non-Caucasian, non-pregnant malaria population groups (
Step 2)
In order to assess the predictive performance in multi-dose studies, three-population groups were developed for Thailand, Papua New Guinea and Sudan females based on published clinical studies within these groups, under conditions of standard multi-dose regimens (10 mg/kg piperaquine base once daily for 3 days) ( Figure 3 ). For all population groups, the majority of estimated parameters (Table 1) fell within 2-3 fold of the reported metrics (Table 2) . Notably, however, for the Thailand population group, the predicted increase in median C max following each dose was only moderately correlated with that reported by Rijken et al. (2011) (Figure 3 ). However, the clinical end-point marker of successful antimalarial therapy (day 7 concentration) (Price et al., 2007) were all simulated (Table 1) to within 2-fold of the reported clinical measures (Table 2 ), in addition to day 14 and day 28 concentrations.
Furthermore, the model predictions were also able of capturing the differences in the day 7 concentration across population groups, despite similar dosing strategies, e.g. Thai 24.74 ng/ml (4.42-64.93 ng/ml) vs. Sudanese 34.0 ng/ml (6.8-86.7 ng/ml) population groups. A one-way ANOVA indicated statistical differences in the median day 7 concentrations, when comparing all four predicted population studies, with the Sudanese population group demonstrating a statistically higher median C max (p = 0.0415) compared with the other population groups.
This highlighted the successful creation of the sub-population group 0 s validation in each population group.
3.3 | Non-Caucasian, pregnant malaria population groups (Step 3)
The PBPK model was further adapted to evaluate the pharmacokinetics of piperaquine in non-Caucasian pregnant population groups ( Figure 4 ). For all population groups, the majority of estimated parameters (Table 3) fell within 2-fold of the reported metrics (Table 4) , with predictions of the median day 7, 14 and 28 concentrations all simulated to within 2-fold of the reported clinical measures (Table 4) .
These predicted point markers were not significantly different than those for non-pregnant subjects (p > 0.05) (Tables 1 and 2 ).
FIGURE 3
The simulated plasma fasted multi-dose concentration-time profile of piperaquine in non-pregnant malaria-female subjects. Multidose simulations of piperaquine (10 mg/kg base once daily for 3 days) were conducted on malaria-non-pregnant female population groups, Thailand (Rijken et al., 2011; Tarning et al., 2012) , Papua New Guinea (Benjamin et al., 2015) and Sudan (Hoglund et al., 2012) , adapted from the 'healthy volunteer' population group with Simcyp with adaptations to the age-weight relationships and blood biochemistry and matching (where possible) the clinical trial design (subject numbers and age range) within Further, the predicted half-life in pregnancy population groups were significantly different (p < 0.01 for all population groups [t-test]) from those in non-pregnancy population groups (Table 3) .
| 'what-if' scenarios (Step 4)
To evaluate and validate the impact of antiretroviral treatment on piperaquine systemic exposure, the only known recent study investigating the impact of antiretroviral (efavirenz) on piperaquine systemic exposure in Ugandan pregnant women (Kajubi et al., 2017b) was replicated, following the creation of a Uganda pregnancy-malaria Figure S1 ). The predicated day 7, 14 and 21 piperaquine concentrations were all within 2-fold of that reported by Kajubi et al.
(2017b), with a similar approximate 50% decrease in the predicted mean day 7 concentrations (No efavirenz: 20.5 ng/ml; efavirenz:
The simulated plasma fasted multi-dose concentration-time profile of piperaquine in pregnant malaria subjects. Multidose simulations of piperaquine (10 mg/kg base once daily for 3 days) were conducted on malaria-pregnant female population groups, Thailand (Rijken et al., 2011; Tarning et al., 2012) , Papua New Guinea (Benjamin et al., 2015) and Additionally, the presence of efavirenz or ritonavir significantly reduced or increased, respectively, the day 7 piperaquine concentration across all population groups, however, the overall impact of the DDI across population groups for both efavirenz and ritonavir was broadly similarly ( Figure 5 ). This resulted in a similar number of subjects attaining a day 7 concentration ≥ 30 ng/ml, except for the Sudanese population with an efavirenz-mediated DDI, where a statistically significant difference in the median day 7 concentration across the three population groups was identified (one-way ANOVA, p = 0.0023).
| 3.4.3 the impact of gestation on the extent of an ART-mediated DDI
In the absence of an antiretroviral-mediated DDIs, the median predicted day 7 concentration was broadly consistent across all gestational weeks investigated (Thailand: 20.2-21.2 ng/ml; Papua New Guinea: 22.5-23.5 ng/ml); Sudan: 25.1-26.2 ng/ml) and demonstrated no significant difference across gestational weeks within the same population group (Figure 6 ).
In the presence of efavirenz, a significant decrease in piperaquine concentrations (p < 0.0001) was simulated across all gestational weeks within each population group (Thailand: 9.8-11.3 ng/ml; Papua New Guinea: 13.2-21.5 ng/ml; Sudan: 15.4-18.3 ng/ml), except for gestational week 40 with the Papua New Guinea population group (Figure 6 ). In the presence of ritonavir, a significant increase in piperaquine concentrations (p < 0.0001) was simulated across all gestational weeks within each population group (Thailand: 34.2-37.9 ng/ml; Papua New Guinea: 40.7-42.2 ng/ml; Sudan:
41.3-46.1 ng/ml). Furthermore, a trend in an increasing median concentration with increasing gestational week was observed for all population groups, although this was not statistically significant ( Figure 6 ).
| DISCUSSION
The treatment of malaria in special populations, such as pregnant women and young children, is complicated by the 'moving-target' during pregnancy, as well as under conditions of altered serum albumin (mimicking severe malaria), and during potential DDIs; these were mediated by common antiretrovirals available for use in pregnant women (efavirenz and ritonavir).
Despite the advantages of PBPK/mechanistic modelling, the application of modelling approaches to the prediction of plasma concentration profiles has largely been based around systems-parameters derived from Caucasian healthy subjects. The base model development in step 1 followed this similar approach, but only to identify and optimise parameters for single dose piperaquine studies.
A common feature of many antimalarials is the large variability in absorption kinetic processes, represented by a highly variable C max , and it was important to capture this, where possible (Borrmann et al., 2010; Sim et al., 2005; Tarning et al., 2014; White, 2013) . To this end, in the absence of appropriate in vitro Caco-2 derived passive permeability (P app ) measures for piperaquine, we applied a first-order absorption model with final estimates of 0.50 for f a and 0.45 h −1 for k a which were able to recover the C max and t max compared with the single-dose studies (Figure 2) . However, to capture the range of reported values (e.g. C max : 14-31.5 μg/l and t max : 2.1-11.7 h) a 50%
CV was applied. It should be noted that an inclusion of a transit absorption model, such as the Simcyp ADAM module, may improve predictions but the lack of appropriate in vitro permeability measures makes this less attractive over a first order model. The development of the base model was successful for single dose studies.
Malaria is endemic in developing countries and this is reflected by the availability of reported clinical studies we identified in which piperaquine was administered to pregnant and non-pregnant women from studies conducted with subjects from Thailand (Rijken et al., 2011; Tarning et al., 2012) , Sudan (Hoglund et al., 2012) and Papua New Guinea (Benjamin et al., 2015) . The application of the 'HealthyVolunteer' population group to simulate piperaquine pharmacokinetics would not be appropriate, given the difference in adult age across these geographic regions (Walpole et al., 2012) and therefore custom age-weight relationships (Hayes et al., 2015) were generated for each population group to develop non-pregnant and pregnant populations from these regions, which incorporated alterations in blood parameters (haematocrit, human serum albumin and alpha-1-acidic glycoprotein) (see supplementary materials Table S1 ). Changes in haematological biochemistry are also common in malaria and it plays a major role in pathogenesis (Bakhubaira, 2013; Maina et al., 2010; van Wolfswinkel et al., 2013) . From a pharmacokinetic perspective, such changes are likely to impact on the blood:plasma ratio, but more importantly the unbound fraction, a key driver for the prediction of clearance, V ss and the DDIs.
The development of appropriate systems-based population groups, specific to the study design is important and highlighted by the stark differences in body weights compared with the 'Healthy Volunteer' population. Using the customised age-weight relationships for the malaria population (see supplementary material), the body weight for Thai (49.65 ± 7.13 kg), Papua New Guinea (58.32 ± 12.2 kg) and Sudan (53.2 kg ± 14.46 kg) were generally consistent and significantly different (p < 0.01) from a standard 'Healthy Volunteer' population group, given an average weight of 66.7 ± 13.1 kg. As dosing for many antimalarial treatments is based on body weight, this may have a direct effect on the dose administered and the resultant determination of endpoint concentrations , particularly considering that dosing in many developing countries is based on age as a surrogate for body weight, in situations where weight facilities are unavailable.
Further, the inclusion of potential alterations in biochemistrybased changes during pregnancy or because of a disease state are
The impact of changes in human serum albumin concentrations on the piperaquine median day 7 concentration in the absence and presence of an efavirenz or ritonavir-mediated DDI. Multidose simulations of PQP (10 mg/kg base once daily for 3 days) were conducted on malaria-pregnant female population groups (Thailand, Papua New Guinea and Sudan). The human serum albumin concentration was fixed at 20 g/l or 50 g/l. Efavirenz (600 mg once daily) (red bars) or ritonavir (100 mg twice daily) (green bars) were orally dosed throughout the simulation time period (30 days) with piperaquine dosed on days 10, 11 and 12. Box and whisker plots represent minimal, 25th percentile, median, 75th percentile and maximum values. Dashed lines indicate the 30 ng/ml clinical efficacy cut-off. Numbers above the box and whisker are median values and the number (n) of subjects with a predicted concentration of over 30 ng/ml is indicated. Vertical drop-lines indicated statistical comparisons between 20 g/l or 50 g/l simulation. Asterisks above the maximum bar indicate statistical significance when compared with black (no DDI) simulations. **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 important if they are thought to impact directly on the resultant pharmacokinetics of antimalarial treatments. Haematological alterations are common in malaria and a marker of the severity of malaria is often determined from changes in serum albumin. Equally, albumin binding is a direct driver for the free fraction of drugs, and any alterations in this may directly impact upon drug distribution and metabolic pathways. Indeed, the stark difference in HSA in the Sudanese (45.5 g/l)
and Thai (33.7 g/l) population illustrates this difference across population groups (see supplementary materials Table S1 ).
For the three population groups developed, model predictions of key pharmacokinetics metrics were within 2-fold of those reported and illustrate the successful prediction of piperaquine in non-pregnant (Table 1 ) (Figure 3 ) and pregnant women (Table 3 ; Figure 4) . Notably, no significant differences in key pharmacokinetic parameters, including day 7 concentrations, were observed between non-pregnant or pregnant population groups, suggesting the systemic exposure of piperaquine is relatively unchanged between the two groups and concurs with other reports of unchanged piperaquine pharmacokinetics in non-pregnant and pregnant populations (Adam et al., 2012; Rijken et al., 2011; Tarning et al., 2012 ). However, model predictions were less successful at predicting the interindividual variability in the range of C max for population groups for each dosing period (Figures 3   and 4 ). This may be partially due to the poor control of food intake during the trial study, e.g. Tarning et al. (2012) , but may also be a feature of the spare collection points around the expected C max for each dosing day compared with the much richer collection over the longer elimination phases . Further, the larger predicted C max for each dosing period could be a result of the splanchnic blood flow (as a result of increased cardiac output) seen in pregnancy (Dawes & Chowienczyk, 2001 ), and which is altered using
The impact of changes in gestational week on median day 7 piperaquine concentration in the absence and presence of a DDI mediated by efavirenz (induction) or ritonavir (inhibition). Multidose simulations of PQP (10 mg/kg base once daily for 3 days) were conducted on malaria-pregnant female population groups (Thailand, Papua New Guinea and Sudan over gestational weeks (GW) 10, 20, 30 and 40. Efavirenz (600 mg once daily) or ritonavir (100 mg twice daily) were orally dosed throughout the simulation time period (30 days) with piperaquine dosed on days 10, 11 and 12. Box and whisker plots represent minimal, 25th percentile, median, 75th percentile and maximum values. Dashed lines indicate the 30 ng/ml clinical efficacy cut-off. Numbers above the box and whisker are median values and the number (n) of subjects with a predicted concentration of over 30 ng/ml is indicated. Horizontal droplines indicate statistical comparisons between each GW in the absence and presence of the antiretroviral. **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001
'Pregnancy' population groups in Simcyp, and hence represents a slight increase in the bioavailability of piperaquine .
During pregnancy, the activity of CYP3A4 is also known to increase (Little, 1999) , directly impacting upon the metabolic clearance of any CYP3A4 substrates. In our simulations, the increasing gestational week had a noticeable impact on the terminal elimination of piperaquine (see supplementary materials Figure S2) , as quantified by a decrease in the terminal elimination half-life of piperaquine in pregnant populations (Table 3 ) compared with non-pregnant populations (Table 1) .
Having established a working PBPK for piperaquine in pregnant females, the importance of the risk of DDIs was next assessed. The only existing study assessing the risk of DDI with piperaquine and antiretroviral (efavirenz) was recently published by Kajubi et al. (2017b) , and demonstrated a 40% reduction in AUC 0-21d along with a 50% reduction in day 7 concentrations, highlighting the potential risk that efavirenz-mediated DDIs pose, and our model was able to recapitulate these changes (see supplementary materials Figure S1 ). As efavirenz is known to induce CYP3A4, the reduction in AUC and day 7 concentration is likely to be a result of this effect (Hariparsad et al., 2004) . Further, this effect would be augmented by the induction of CYP3A4
itself during pregnancy, as noted for other drugs (Costantine, 2014; Dawes & Chowienczyk, 2001) , and therefore would likely reduce day 7 concentrations below the clinical efficacy end-point of 30 ng/ml (Price et al., 2007) . Indeed, our model simulation demonstrated the impact of this in non-pregnant, pregnant and pregnant + EFV populations, demonstrating the additive effect of efavirenz-mediated DDI and pregnancy-related induction of CYP3A4 expression (see supplementary materials Figure S1 ).
Although pregnancy has been associated with a reduction in haematological parameters, e.g. human serum albumin (decrease by 1% at week 8 and 12% at week 32; Murphy, Scott, McPartlin, & FernandezBallart, 2002) , the impact of such changes on the pharmacokinetics of highly bound drugs is not well characterised in malarial infected subjects. Further, as demonstrated by the development of specific populations, the overall haematological levels are often reduced in such populations. It has also been speculated that P. falciparum plays a major role in the proteolysis of albumin (El Tahir, Malhotra, & Chauhan, 2003; Kolakovich, Gluzman, Duffin, & Goldberg, 1997) . Further, previous reports have demonstrated an alteration in fu plasma for quinine (Mansor et al., 1991) and halofantrine (Cenni, Meyer, Brandt, & Betschart, 1995) during the progression of malaria. In attempting to assess the impact of potential changes in human serum albumin on the overall extent of antiretroviral-mediated DDIs (by assessing the change in the piperaquine day 7 concentration), the HSA concentration was set to 20 g/l (severe malaria) and 50 g/l (healthy subjects).
In all cases (absence and presence of an antiretroviral) and in all population groups, the change from 20 g/l to 50 g/l had a direct effect on day 7 concentrations, leading to a statistically significant increase ( Figure 5 ). For all population groups developed, the reduction in HSA to 20 g/l, generally resulted in a statistically significant increase in piperaquine fu plasma (p < 0.001) that subsequently propagated to an increase in the hepatic clearance (p < 0.001), when compared with healthy volunteer population groups. This trend was also demonstrated under conditions of efavirenz/ritonavir exposure when compared with non-DDI studies (see Table 5 for a representative illustration in the Thailand non-pregnant population). The impact of this combined reduction in the baseline HSA concentration in the malaria population coupled with the pregnancy-related reduction in HSA is important considering that it can directly impact upon the elimination of the drug.
As expected, the impact of efavirenz and ritonavir on day 7 concentration were in-line with their function as CYP3A4 inducers (efavirenz) and inhibitors (ritonavir) resulting in a direct effect on day 7 concentration following the interaction ( Figure 5) . A reduction in antimalarial treatment concentrations as a result of induction will lead to parasite recrudescence, as has been demonstrated for lumefantrine (Huang et al., 2012 ; WorldWide Antimalarial Resistance Network Lumefantrine PK/PD Study Group, 2015) , dihydroartemisinin (Lamorde et al., 2013) and piperaquine (Kajubi et al., 2017b) . Further, piperaquine is known to prolong QTc in a concentration dependent manner (Darpo et al., 2015) , and an increased concentration following inhibition of metabolic clearance may potentially lead to QTc prolongation, as demonstrated with an adapted 2 day treatment with DHA-PQ (Manning et al., 2014) .
Physiological changes during gestation can result in significant changes in plasma volume, CYP expression and cardiac output (Costantine, 2014; Dawes & Chowienczyk, 2001) , it would therefore be expected that significant changes in the pharmacokinetics would be expected during pregnancy. The impact of gestation on the predicted day 7 concentrations was explored in the three pregnant population groups.
In all three populations, the baseline median day 7 concentration was consistent across all population groups and with increasing GW, approximately 20-26 ng/ml, with no significant differences when GW increased (Figure 6 ). Given the long half-life of piperaquine, the impact of gestation on day 7 concentrations may not be significantly noticeable. However, CYP3A4 activity is thought to increase during pregnancy, reaching a peak at approximately week 20-24 (Hebert et al., 2008; Hirt et al., 2006; Villani et al., 2006) . When considering the Thai population as an example, at baseline, GW 20 corresponded to the lowest median day 7 concentration and the highest hepatic CL int (week 17-27) (see supplementary materials Figure S3 ). However, the impact of this may be negligible given the long half-life and large volume of distribution of piperaquine (Adam et al., 2012; Benjamin et al., 2015; Rijken et al., 2011; Tarning et al., 2013) . Table S1 ).
Thus, although the impact of antiretrovirals on piperaquine pharmacokinetics in pregnancy may lead to treatment failure or an increase in the adverse effects, the overall effect and magnitude of the DDI during pregnancy is largely minimal, with little change in the day 7
concentrations.
It should be noted that the population groups developed altered only the age-weight relationships and haematological parameters, and reflected changes in predominantly malaria-infected subjects.
Genetic polymorphisms in CYP2B6 are common (Haas et al., 2009; Lang et al., 2001; To et al., 2009 ) and may impact on the clearance of efavirenz and hence its ability to elicit a DDI, and CYP2B6 population-based polymorphic changes were not incorporated into our customised population groups. Further, changes in the abundance of CYP-isozymes across population groups have also not been incorporated and this may enable better predictions of the terminal elimination phases for piperaquine across population groups (Bains, 2013) . It should also be noted that only one previous study reported piperaquine metabolic pathways (Lee et al., 2012) and our assumption of the fraction metabolised by CYP3A4 and CYP2B6 of 0.99 and 0.01, alongside the parameter estimated CL int , may be optimised at a later date with in vitro metabolic clearance data to enhance the application of the model, when such data become available.
Further, the complexity of diseases states which can present differently depending upon disease progress, as is common with malaria and HIV (Wanke et al., 2000) , would dictate that the developed population groups should address these different stages of disease progression. Finally, the studies used for validation utilised two DHA-PQ combination formulation regimens, Eurartesim® (Sigma-Tau, Rome, Italy) or Artekin® (Holleykin Pharmaceutical Co., Guangzhou, China).
However, only Eurartesim® has gained Good Manufacturing Practice compliance, having been developed without the Medicines for Malaria Venture (MMV) (Ubben & Poll, 2013) . Therefore, batch-to-batch vari- Impact of changes in blood biochemistry on hepatic clearance in the absence and presence of a efavirenz or ritonavir mediated drug-drug interaction for a representative population group (Thailand non-pregnant) processes in greater mechanistic detail. The modelling of the absorption phase of piperaquine pharmacokinetics may therefore be improved when such information becomes available.
| CONCLUSION
The present PBPK model provides the ability mechanistically to predict the pharmacokinetic of piperaquine in non-pregnant and pregnant women, whilst also considering possible population differences in malaria-HIV co-infected subjects. The present model demonstrated that piperaquine pharmacokinetics in pregnancy is consistent and was relatively unchanged, compared with non-pregnant women and that the impact of antiretroviral-mediated DDIs can significantly alter the piperaquine pharmacokinetics, the magnitude of which was generally consistent across gestational weeks. Further adaption of the model presented is warranted and would require further detailed collation of relevant physiological and biochemical alterations common to HIV/ malaria patients and which would further enhance the clinical application of the proposed model.
